FDA Proposes Rule Allowing NAC Products to Be Marketed as Dietary Supplements

The U.S. Food and Drug Administration (FDA) on November 16 issued a proposed rule that, if finalized, would reverse the exclusion of N-acetyl-L-cysteine (NAC) from the definition of "dietary supplement," allowing NAC-containing products to be lawfully marketed as dietary supplements provided they do not otherwise violate the Federal Food, Drug, and Cosmetic Act. The proposed rule will be open to public comment for 60 days.
In a March 2022 response to two citizen petitions, the FDA had said NAC-containing products cannot be dietary supplements. In August 2022, the agency issued final guidance explaining its intent to exercise temporary enforcement discretion for certain NAC products labeled as dietary supplements, and said it intends to continue that policy while the rulemaking proceeds.
The FDA said a comprehensive review did not identify any safety concerns with the use of NAC in or as a dietary supplement, and that NAC products represented as dietary supplements have been sold in the United States for over 30 years, with consumers continuing to seek access to them. The rule would create a regulation entitled "Dietary Ingredients Not Excluded from the Dietary Supplement Definition," with NAC as the first ingredient listed — the FDA's first use of this rulemaking authority.
The agency said the action, if finalized, would be a deregulatory action under President Trump's Executive Order 14192. Details on how to submit a comment are in the Federal Register notice.
(Source: U.S. Food and Drug Administration)
Source: U.S. Food and Drug Administration
Published by GSM · USA (original Chinese edition)
Photo: 图:美国食品药品监管局(FDA)总部大楼。GSM固定图库,官方建筑照片。 / Photo: U.S. Food and Drug Administration headquarters. GSM asset library, official building photo.
UK Health Security Agency Report on November 12: Influenza Positivity in England Reached 13.1% in Week 45, Up From 12.3%, With Activity at Low Circulating Levels2026-11-16
EMA's CHMP Meeting of November 9-12: Seven New Medicines Recommended for Approval, With Indication Extensions Recommended for 11 More2026-11-16